ABSTRACT
First-Generation PS ODNs..................................................................................................276 10.4 Multiple Antisense Mechanisms Can Utilize 2-MOE Modifications................................277 10.5 In Vitro Pharmacological Properties of 2-MOE Gapmers .................................................279 10.6 In Vivo Pharmacological Properties of 2-MOE Gapmers ..................................................282
